Recognizes an oncofetal antigen of 220kD, identified as a tumor-associated glycoprotein (TAG-72) with properties of a mucin. This monoclonal antibody defines the mucin-carried sialylated-Tn epitope. TAG-72 is usually expressed by adenocarcinomas, but is negative in mesotheliomas. Studies have reported that this antibody has 80% sensitivity and 93% specificity for pulmonary adenocarcinoma. Therefore, TAG-72 is a useful marker to distinguish between mesothelioma and adenocarcinoma. However, false positive reactions can occur so results must be interpreted with the utmost caution. This antibody may be useful in the differentiation of non-small cell carcinomas from small cell carcinomas of the lung. The combined use of anti-TAG-72 and anti-GCDFP-15 is valuable in the diagnosis of apocrine carcinoma.
Applications
Suitable for use in FLISA, Western Blot, Flow Cytometry, Immunoprecipitation, Immunofluorescence and Immunohistochemistry. Other applications not tested.
Recommended Dilution
Flow Cytometry: 0.5-1ug/10e6 cells Western Blot: 0.5-1ug/ml Immunofluorescence: 1-2ug/ml Immunoprecipitation: 1-2ug/500ug protein lysate Immunohistochemistry (Frozen & Formalin fixed paraffin embedded): 0.5-1ug/ml/30min @ RT Optimal dilutions to be determined by the researcher.
Positive Control
Jurkat cells, Breast or lung carcinoma.
Storage and Stability
May be stored at 4°C before opening. DO NOT FREEZE! Stable at 4°C as an undiluted liquid. Dilute only prior to immediate use. Stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. APC is light sensitive.
Note: Applications are based on unconjugated antibody.
Immunogen
Membrane-enriched fraction of a human breast carcinoma liver metastasis
Form
Supplied as a liquid in PBS, pH 7.2. Labeled with Allophycocyanin (APC).
Purity
Purified by Protein G affinity chromatography.
Specificity
Recognizes human TAG-72. Species Crossreactivity: bovine, canine, hamster and rat. Stains the majority of human adenocarcinomas including colorectal, pancreatic, gastric, ovarian, endometrial, mammary and non-small cell lung cancer.